英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字,中文词皆可:


请选择你想看的字典辞典:
单词字典翻译
340584查看 340584 在百度字典中的解释百度英翻中〔查看〕
340584查看 340584 在Google字典中的解释Google英翻中〔查看〕
340584查看 340584 在Yahoo字典中的解释Yahoo英翻中〔查看〕





安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Ibrutinib Resistance Mechanisms and Treatment Strategies for . . .
    BTK is a central contributor to B-cell lymphoma pathogenesis, as it is significantly more active (increased phosphorylation) in B-cell lymphomas than in normal B-cells Additionally, BTK plays a fundamental role in modulating chemokine and integrin signaling (CXCR4), thereby regulating B-cell trafficking and tissue homing [ 7 ]
  • Ibrutinib improves diffuse large B-cell lymphoma survival
    NCI researchers have found that adding the targeted therapy ibrutinib (Imbruvica) to standard chemotherapy can improve how long some younger people with a specific form of diffuse large B-cell lymphoma live The new findings come from a new analysis of a previously conducted phase 3 clinical trial called Phoenix
  • Imbruvica (Ibrutinib) | Lymphoma News Today
    A total of 56 patients with various types of B-cell NHL were enrolled in the study The results showed that Imbruvica was well-tolerated across various types of B-cell NHL The FDA approved Imbruvica in 2013 for the treatment of patients with MCL based on the results of an open-label Phase 2 trial (NCT01236391) During the trial, 111 patients
  • How Does IMBRUVICA® Work? - CLL SLL | IMBRUVICA® (ibrutinib)
    The most common side effects of IMBRUVICA® in adults with B-cell malignancies (CLL SLL and WM) include low platelet count; diarrhea; tiredness; muscle, bone, and joint pain; low white blood cell count; rash; low red blood cell count (anemia); bruising; and nausea
  • Ibrutinib improves survival for younger people with diffuse . . .
    “This new analysis provides a compelling rationale for doctors to consider adding ibrutinib to standard chemotherapy for the initial treatment of younger patients with non-GCB DLBCL,” said Wyndham H Wilson, M D , Ph D , senior investigator in the Lymphoid Malignancies Branch and a co-author of the study DLBCL is the most common type of
  • Ibrutinib in Patients with Relapsed or Refractory Diffuse . . .
    Based on gene profiling, DLBCL can be further classified as activated B-cell-like lymphoma (ABC), germinal center B-cell-like lymphoma (GCB) and primary mediastinal B-cell lymphoma Most patients of DLBCL achieve complete remission (CR) after treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), which is
  • Your Guide to Your IMBRUVICA (ibrutinib) Treatment Plan
    IMBRUVICA® may cause serious side effects, including: Infections can happen during treatment with IMBRUVICA® These infections can be serious and may lead to death Tell your healthcare provider right away if you have fever, chills, weakness, confusion, or other signs or symptoms of an infection during treatment with IMBRUVICA® B cell BTK
  • IMBRUVICA® (ibrutinib) receives positive CHMP opinion for the . . .
    2 Dreyling, et al Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell
  • Ibrutinib Treatment: Uses, Dosage, Side Effects, and Cost Guide
    Treatment should continue until the disease progresses or unacceptable side effects occur Ibrutinib for Diffuse Large B-Cell Lymphoma (DLBCL) Recommended dose: 560 mg orally once daily Treatment should continue until the disease progresses or unacceptable side effects occur Dosage Forms and Strengths
  • Official Healthcare Professional Website | IMBRUVICA . . .
    Cytopenias: In 645 patients with B-cell malignancies who received IMBRUVICA ® as a single agent, grade 3 or 4 neutropenia occurred in 23% of patients, grade 3 or 4 thrombocytopenia in 8%, and grade 3 or 4 anemia in 2 8%, based on laboratory measurements Monitor complete blood counts monthly
  • Ibrutinib as first-line therapy for mantle cell lymphoma: a . . .
    Advanced stage mantle cell lymphoma (MCL) is an incurable B-cell malignancy with a wide spectrum of clinical presentations and management approaches spanning active surveillance for asymptomatic and clinically indolent disease to urgent immunochemotherapy for aggressive variants 1 Selected fitter patients can achieve long remissions after intensive cytarabine- and rituximab-containing
  • Imbruvica gets positive EMA Committee opinion for untreated . . .
    Imbruvica gets positive EMA Committee opinion for untreated mantle cell lymphoma eligible for Stem Cell Transplant: Janssen-Cilag International Written By : Ruchika Sharma | Medically Reviewed By : Dr Kamal Kant Kohli Published On 2025-06-22T17:30:45+05:30 | Updated On 22 Jun 2025 5:31 PM IST





中文字典-英文字典  2005-2009